Ventricular tachyarrhythmias (out-of-hospital cardiac arrests)

Eddy S. Lang, Marwan Al Raisi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

INTRODUCTION: Pulseless ventricular tachycardia and ventricular fibrillation are the main causes of sudden cardiac death, but other ventricular tachyarrhythmias can occur without haemodynamic compromise. Ventricular arrhythmias occur mainly as a result of myocardial ischaemia or cardiomyopathies, so risk factors are those of cardiovascular disease.

METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiarrhythmic drug treatments and defibrillation for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? What are the effects of antiarrhythmic drug treatments for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

RESULTS: We found 11 systematic reviews and RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bretylium, lidocaine, amiodarone, procainamide, and defibrillation.

Original languageEnglish
JournalBMJ clinical evidence
Volume2006
Publication statusPublished - 2006

Fingerprint

Out-of-Hospital Cardiac Arrest
Ventricular Fibrillation
Ventricular Tachycardia
Tachycardia
Anti-Arrhythmia Agents
Shock
Procainamide
Amiodarone
Sudden Cardiac Death
United States Food and Drug Administration
Lidocaine
Cardiomyopathies
Libraries
Myocardial Ischemia
Cardiac Arrhythmias
Cardiovascular Diseases
Hemodynamics
Organizations
Databases
Delivery of Health Care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ventricular tachyarrhythmias (out-of-hospital cardiac arrests). / Lang, Eddy S.; Al Raisi, Marwan.

In: BMJ clinical evidence, Vol. 2006, 2006.

Research output: Contribution to journalReview article

@article{03a90e1c583f47948227468fba8334c7,
title = "Ventricular tachyarrhythmias (out-of-hospital cardiac arrests)",
abstract = "INTRODUCTION: Pulseless ventricular tachycardia and ventricular fibrillation are the main causes of sudden cardiac death, but other ventricular tachyarrhythmias can occur without haemodynamic compromise. Ventricular arrhythmias occur mainly as a result of myocardial ischaemia or cardiomyopathies, so risk factors are those of cardiovascular disease.METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiarrhythmic drug treatments and defibrillation for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? What are the effects of antiarrhythmic drug treatments for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).RESULTS: We found 11 systematic reviews and RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bretylium, lidocaine, amiodarone, procainamide, and defibrillation.",
author = "Lang, {Eddy S.} and {Al Raisi}, Marwan",
year = "2006",
language = "English",
volume = "2006",
journal = "Clinical evidence.",
issn = "1752-8526",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Ventricular tachyarrhythmias (out-of-hospital cardiac arrests)

AU - Lang, Eddy S.

AU - Al Raisi, Marwan

PY - 2006

Y1 - 2006

N2 - INTRODUCTION: Pulseless ventricular tachycardia and ventricular fibrillation are the main causes of sudden cardiac death, but other ventricular tachyarrhythmias can occur without haemodynamic compromise. Ventricular arrhythmias occur mainly as a result of myocardial ischaemia or cardiomyopathies, so risk factors are those of cardiovascular disease.METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiarrhythmic drug treatments and defibrillation for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? What are the effects of antiarrhythmic drug treatments for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).RESULTS: We found 11 systematic reviews and RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bretylium, lidocaine, amiodarone, procainamide, and defibrillation.

AB - INTRODUCTION: Pulseless ventricular tachycardia and ventricular fibrillation are the main causes of sudden cardiac death, but other ventricular tachyarrhythmias can occur without haemodynamic compromise. Ventricular arrhythmias occur mainly as a result of myocardial ischaemia or cardiomyopathies, so risk factors are those of cardiovascular disease.METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiarrhythmic drug treatments and defibrillation for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? What are the effects of antiarrhythmic drug treatments for use in out-of-hospital cardiac arrest associated with shock-resistant ventricular tachycardia or ventricular fibrillation? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).RESULTS: We found 11 systematic reviews and RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bretylium, lidocaine, amiodarone, procainamide, and defibrillation.

UR - http://www.scopus.com/inward/record.url?scp=84983087676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983087676&partnerID=8YFLogxK

M3 - Review article

VL - 2006

JO - Clinical evidence.

JF - Clinical evidence.

SN - 1752-8526

ER -